secwatch.observer — SEC 8-K summary
======================================

Issuer:     MBX Biosciences, Inc. (MBX)
CIK:        0001776111
Form:       8-K
Filed at:   2025-01-07T23:59:59+00:00
Accession:  0000950170-25-002555
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MBX Biosciences announces positive Phase 1 topline results for MBX 1416 for PBH; cash $262.1M
--------------------------------------------------------------------------------

- MBX 1416 generally well-tolerated; no dose-related serious adverse events; mild/moderate ISRs in 88% resolved ~7 days.
- Median half-life ~90 hours supports once-weekly dosing; Tmax 36-48h at steady state; dose-proportional PK.
- GLP-1 increase within 60 mins of mixed meal test; slight acceleration of gastric emptying observed.
- No meaningful effect on rosuvastatin exposure in drug-drug interaction portion.
- Phase 2 in PBH patients expected to start 2H 2025; cash $262.1M as of Dec 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1776111/000095017025002555/0000950170-25-002555-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1776111/000095017025002555/mbx-20250107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-002555

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer